Minoxidil
SIGMA/M4145 - ≥99% (TLC)
Synonym: 6-
CAS Number: 38304-91-5
Empirical Formula (Hill Notation): C9H15N5O
Molecular Weight: 209.25
EC Number: 253-874-2
MDL Number: MFCD00063409
Linear Formula: C9H15N5O
Product Type: Chemical
| assay | ≥99% (TLC) |
| InChI | 1S/C9H15N5O/c10-7-6-8(12- |
| InChI key | ZIMGGGWCDYVHOY-UHFFFAOYSA |
| mp | 272-274 °C (dec.) (lit.) |
| originator | Johnson & Johnson |
| Quality Level | 100 ![]() |
| SMILES string | NC1=CC(=NC(=N)N1O)N2CCCCC |
| Application: | Minoxidil has been used as test drug: • in dermal papilla spheroid model, to study the effect of hair regeneration • administered orally to experimental rats, in the approach to identify biomarkers of drug induced vascular injury • administered via oral gavage to nonhuman primate model in order to study its effect on tilt responses |
| Biochem/physiol Actions: | Activates ATP-activated K+ channels; vasodilator; slow or stop hair loss and promote hair regrowth. |
| Biochem/physiol Actions: | Minoxidil is originally used to treat hypertension, which also induces hypertrichosis. It is considered as a potent drug for treating androgenetic alopecia. |
| Features and Benefits: | This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | ≥99% (TLC) |
| mp | 272-274 °C (dec.) (lit.) |
| UNSPSC | 12352200 |


